Antihyperglycemics (SGLT2 inhibitors)
- T2DM drugs with major HF/renal benefit
- Benefits extend beyond glucose lowering
- HF/CKD: empa/dapagliflozin lead
- Modest weight + BP reduction
- Genital mycosis + volume depletion
- Rare euglycemic DKA; hold with fasting
- Glycemic effect wanes at low eGFR
- Can lower serum lithium
Class at a glance
- T2DM drugs with major HF/renal benefit
Clinical role
- Benefits extend beyond glucose lowering
- HF/CKD: empa/dapagliflozin lead
- Genital mycosis + volume depletion
Members / distinctions
- Rare euglycemic DKA; hold with fasting
- Glycemic effect wanes at low eGFR
- Can lower serum lithium
Practical pearls
- Modest weight + BP reduction
Self-check
- Which benefits distinguish SGLT2 inhibitors beyond glucose lowering?
HF/renal benefits. - How can SGLT2 inhibitors affect serum lithium?
They can lower it.
Drugs in this class (5)
Antihyperglycemics (SGLT2 inhibitors) prescription history
Animated chart of estimated U.S. prescriptions per year, Diabetes meds (1923–2026). SGLT2 inhibitor highlighted from 2013.
All drug classes · Open Antihyperglycemics (SGLT2 inhibitors) in the interactive console ↗